Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 09 Jun 2014
At a glance
- Drugs AAV-IFNA2B gene therapy Medgenics (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Aevi Genomic Medicine
- 10 Jun 2017 Biomarkers information updated
- 16 Apr 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 09 Nov 2011 Planned initiation date changed from 1 Oct 2011 to 1 Jun 2012, according to a Medgenics media release.